We are live on ! Find out more
EBS icon

Emergent Biosolutions
EBS

238 hedge funds and large institutions have $1.88B invested in Emergent Biosolutions in 2017 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 104 increasing their positions, 60 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

373% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 104 | Existing positions reduced: 60

25% more capital invested

Capital invested by funds: $1.5B → $1.88B (+$378M)

20% more funds holding

Funds holding: 198 → 238 (+40)

7.58% more ownership

Funds ownership: 90% → 97.58% (+7.6%)

47% less call options, than puts

Call options by funds: $684K | Put options by funds: $1.29M

Holders
238
Holders Change
+40
Holders Change %
+20.2%
% of All Funds
5.4%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.07%
New
52
Increased
104
Reduced
60
Closed
11
Calls
$684K
Puts
$1.29M
Net Calls
-$609K
Net Calls Change
-$1.63M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$24.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$18.2M
3
AAMU
Amundi Asset Management US
Massachusetts
+$14.9M
4
O
OppenheimerFunds
New York
+$13.6M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$11.1M

Top Sellers

Rank Fund Capital Flow
1
GT
Glenmede Trust
Pennsylvania
-$22.3M
2
Fidelity International
Fidelity International
Bermuda
-$11.2M
3
Charles Schwab
Charles Schwab
California
-$6.03M
4
GAM
Gotham Asset Management
New York
-$4.93M
5
Bank of America
Bank of America
North Carolina
-$4.85M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
151
Aperio Group
California
$618K +$19.6K +465 +4%
CSS
152
Cubist Systematic Strategies
Connecticut
$613K +$312K +7,407 +128%
RFC
153
Regions Financial Corp
Alabama
$588K -$526K -12,505 -50%
LTFS
154
Ladenburg Thalmann Financial Services
Florida
$587K +$2.1K +50 +0.4%
FQ
155
First Quadrant
California
$572K +$355K +8,431 +217%
HI
156
HBK Investments
Texas
$572K +$518K +12,300 New
Teacher Retirement System of Texas
157
Teacher Retirement System of Texas
Texas
$549K +$497K +11,814 New
AA
158
AlphaMark Advisors
Kentucky
$536K +$485K +11,527 New
CGH
159
Crossmark Global Holdings
Texas
$534K +$185K +4,390 +62%
BCM
160
Brasada Capital Management
Texas
$511K +$463K +11,000 New
Citadel Advisors
161
Citadel Advisors
Florida
$498K -$263K -6,251 -37%
TI
162
Trexquant Investment
Connecticut
$494K +$448K +10,635 New
MLICM
163
Metropolitan Life Insurance Company (MetLife)
New York
$491K -$535K -12,706 -55%
WC
164
Woodstock Corp
Massachusetts
$482K -$111K -2,643 -20%
CAAS
165
Capital Asset Advisory Services
Michigan
$473K -$90K -2,138 -17%
BCM
166
Bayesian Capital Management
New York
$469K +$424K +10,084 New
ONB
167
Old National Bancorp
Indiana
$466K +$422K +10,030 New
SKK
168
Shepherd Kaplan Krochuk
Massachusetts
$462K – – –
Susquehanna International Group
169
Susquehanna International Group
Pennsylvania
$461K +$417K +9,914 New
MSA
170
Mason Street Advisors
Wisconsin
$425K +$11.7K +279 +3%
VF
171
Virtu Financial
New York
$425K +$385K +9,149 New
JMPWA
172
JP Morgan Private Wealth Advisors
California
$421K +$7.87K +187 +2%
YMRC
173
Yorktown Management & Research Company
Virginia
$400K – – –
RJA
174
Raymond James & Associates
Florida
$356K – – –
FRM
175
Fox Run Management
Connecticut
$356K +$322K +7,654 New
5 6
7
8 9

EBS Hedge Fund Activity: Q4 2017 in Review

238 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q4 2017, worth a combined $1.88B — up 25% from $1.5B a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new EBS positions and 11 closed out — a net gain of 41 holders — while 104 added to existing stakes and 60 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $24.3M. The largest seller was Glenmede Trust, cutting an estimated $22.3M.

  • 238 institutional investors held Emergent Biosolutions (EBS) as of Q4 2017, up from 198 in Q3 2017.
  • Funds reported $1.88B of Emergent Biosolutions stock for Q4 2017, up 25% quarter-over-quarter.
  • 52 funds opened new Emergent Biosolutions positions in Q4 2017 and 11 closed out, a net change of +41 holders.
  • The largest Emergent Biosolutions buyer in Q4 2017 was Goldman Sachs, an estimated $24.3M added.
  • The largest Emergent Biosolutions seller in Q4 2017 was Glenmede Trust, an estimated $22.3M sold.

Based on aggregated 13F filings for Q4 2017.